vialroom

#retatrutide 2026-01-16

Friday49 messages14 participantstimes are UTC
Highlights from this day
  • lean_mass_lex — thats the whole argument and it hasnt changed 22:57
  • dana_titrates — which about half the channel ignores 23:11
  • juniper_joins — that makes sense. thanks for answering seriously 23:21
P2

buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely, i think

research use only is on every vial and i treat it as exactly that, nobody here is prescribing

follow up the half life supports weekly dosing and thats what ive done from the start

follow up phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan

BW

lost 40kg over 7 months at doses well under what the trials used

🤝1🙏12
YV

phase 2 was still trending at the end which is why the phase 3 readout matters more than usual, not advice obviously

i said 3 months ago that my heart rate had settled and it has stayed settled since

i was wrong to call the heart rate a non issue last year, enough people logged it that i changed my mind

TW

ok so triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history

🧪11❤️2
VV

whats a sensible starting point, im seeing everything from 0.5 to 2

TW

i log resting heart rate every morning because of this and its the one number i actually watch

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

triple agonist meaning GLP-1, GIP and glucagon, have i got that right

stepping in 1.7 increments instead of doubling is the only thing i would change if i started again
research use only is on every vial and i treat it as exactly that, nobody here is prescribing

TT

came off at 14 weeks because my resting rate stayed elevated and i didnt like it

P2

does the energy expenditure claim show up as anything you can feel

back after 21 months, has anything actually been published since

JJ

genuine question and im not trying to start anything. why does this channel exist if the compound isnt approved

QH

fair question and its been asked properly about twice a year since 2023

the archive exists because people are going to do this whether or not there is somewhere to write it down

somewhere to write it down means the heart rate logs exist, the bad lots get named, and the person at 71 bpm sees that someone else held their dose

QH

never. nobody in here has the standing to and the ones who try get told

SB

and i will keep saying the boring part. no approval means no long term safety dataset. not a reassuring absence, an actual absence

SB

the outcomes trial in the TRIUMPH programme reporting, honestly. thats the one i am waiting on

LM

and until then the community line has been low and slow, log everything, and dont chase the 24%

LM

about half. the other half write it down, which is why the logs are useful

VI

we nearly did not open this channel. the deciding argument was that people were already discussing it in #other-peptides with no test data attached

at least here the discussion drags a COA along behind it

DT

also read #scam-watch before you buy anything labelled reta. the fake rate on this one has been the worst of any compound we track

SB

there have been vials that assayed as tirzepatide, vials that assayed as nothing much, and one memorable lot that was a GLP-1 that nobody could identify

SB

you pay for mass spec. Janoshik will tell you what is actually in there, not just how pure the thing you hoped for was

SB

much less true of sema. that has years of cardiovascular outcome data now. tirz is catching up. reta has 48 weeks and a promise